Oncological outcome of surgical management in patients with
recurrent uterine cancer-a multicenter retrospective cohort
study-CEEGOG EX01 Trial

J 2019

Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial

GERMANOVA, Anna, Francesco RASPAGLIESI, Luis CHIVA, Ladislav DUŠEK, Macit ARVAS et. al.

Základní údaje

Originální název

Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial

Autoři

GERMANOVA, Anna (203 Česká republika, garant), Francesco RASPAGLIESI (380 Itálie), Luis CHIVA (724 Španělsko), Ladislav DUŠEK (203 Česká republika, domácí), Macit ARVAS (792 Turecko), Eric LEBLANC (250 Francie), Tibor LENGEYL (703 Slovensko), Violante DI DONATO (380 Itálie), Afra ZAAL (528 Nizozemské království), Polat DURSUN (792 Turecko), Ignacio ZAPARDIEL (724 Španělsko), Taner TURAN (792 Turecko), Sergio Augusto TRIGINELLI (76 Brazílie), Sang Wun KIM (410 Korejská republika), Matias JURADO (724 Španělsko), Jalid SEHOULI (276 Německo), Borek SEHNAL (203 Česká republika), Ladislav MASAK (703 Slovensko), Nicolae IOANID (642 Rumunsko), Greta DREYER (710 Jižní Afrika), Robert JACH (616 Polsko), Milos MLYNCEK (703 Slovensko), Valentina CHIAPPA (380 Itálie), Fabio MARTINELLI (380 Itálie), Jiri SLAMA (203 Česká republika), Giorgio BOGANI (380 Itálie), Roman KOCIAN (203 Česká republika) a David CIBULA (203 Česká republika)

Vydání

International Journal of Gynecological Cancer, Philadelphia, Lippincott Williams & Wilkins, 2019, 1048-891X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.095

Kód RIV

RIV/00216224:14110/19:00110182

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1136/ijgc-2019-000292

UT WoS

000469455500009

Klíčová slova anglicky

uterine cancer

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 09:44, Mgr. Tereza Miškechová

Anotace

V originále

Objectives To assess the survival of patients who have received an operation for recurrent cervical and endometrial cancer and to determine prognostic variables for improved oncologic outcome. Methods A retrospective multicenter analysis of the medical records of 518 patients with cervical (N = 288) or endometrial cancer (N = 230) who underwent surgery for disease recurrence and who had completed at least 1 year of follow-up. Results The median survival reached 57 months for patients with cervical cancer and 113 months for patients with endometrial cancer after surgical treatment of recurrence (p = 0.036). Histological sub-type had a significant impact on overall survival, with the best outcome in endometrial endometrioid cancer (121 months), followed by cervical squamous cell carcinoma, cervical adenocarcinoma, or other types of endometrial cancer (81 vs 35 vs 35 months; p<0.001). The site of recurrence did not significantly influence survival in cervical or in endometrial cancer. Cancer stage at first diagnosis, tumor grade, lymph node status at recurrence, progression-free interval after first diagnosis, and free resection margins were associated with improved overall survival on univariate analysis. On multivariate analysis, the stage at first diagnosis and resection margins were significant independent predictive parameters of an improved oncologic outcome. Conclusion Long-term survival can be achieved via secondary cytoreductive surgery in selected patients with recurrent cervical and endometrial cancer. An excellent outcome is possible even if the recurrence site is located in the lymph nodes. The possibility of achieving complete resection should be the main criterion for patient selection.

Citovat

GERMANOVA, Anna, Francesco RASPAGLIESI, Luis CHIVA, Ladislav DUŠEK, Macit ARVAS, Eric LEBLANC, Tibor LENGEYL, Violante DI DONATO, Afra ZAAL, Polat DURSUN, Ignacio ZAPARDIEL, Taner TURAN, Sergio Augusto TRIGINELLI, Sang Wun KIM, Matias JURADO, Jalid SEHOULI, Borek SEHNAL, Ladislav MASAK, Nicolae IOANID, Greta DREYER, Robert JACH, Milos MLYNCEK, Valentina CHIAPPA, Fabio MARTINELLI, Jiri SLAMA, Giorgio BOGANI, Roman KOCIAN a David CIBULA. Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial. International Journal of Gynecological Cancer. Philadelphia: Lippincott Williams & Wilkins, 2019, roč. 29, č. 4, s. 711-720. ISSN 1048-891X. Dostupné z: https://dx.doi.org/10.1136/ijgc-2019-000292.

@article{1545822,
   author = {Germanova, Anna and Raspagliesi, Francesco and Chiva, Luis and Dušek, Ladislav and Arvas, Macit and Leblanc, Eric and Lengeyl, Tibor and Di Donato, Violante and Zaal, Afra and Dursun, Polat and Zapardiel, Ignacio and Turan, Taner and Triginelli, Sergio Augusto and Kim, Sang Wun and Jurado, Matias and Sehouli, Jalid and Sehnal, Borek and Masak, Ladislav and Ioanid, Nicolae and Dreyer, Greta and Jach, Robert and Mlyncek, Milos and Chiappa, Valentina and Martinelli, Fabio and Slama, Jiri and Bogani, Giorgio and Kocian, Roman and Cibula, David},
   article_location = {Philadelphia},
   article_number = {4},
   doi = {http://dx.doi.org/10.1136/ijgc-2019-000292},
   keywords = {uterine cancer},
   language = {eng},
   issn = {1048-891X},
   journal = {International Journal of Gynecological Cancer},
   title = {Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial},
   url = {http://dx.doi.org/10.1136/ijgc-2019-000292},
   volume = {29},
   year = {2019}
}

TY  - JOUR
ID  - 1545822
AU  - Germanova, Anna - Raspagliesi, Francesco - Chiva, Luis - Dušek, Ladislav - Arvas, Macit - Leblanc, Eric - Lengeyl, Tibor - Di Donato, Violante - Zaal, Afra - Dursun, Polat - Zapardiel, Ignacio - Turan, Taner - Triginelli, Sergio Augusto - Kim, Sang Wun - Jurado, Matias - Sehouli, Jalid - Sehnal, Borek - Masak, Ladislav - Ioanid, Nicolae - Dreyer, Greta - Jach, Robert - Mlyncek, Milos - Chiappa, Valentina - Martinelli, Fabio - Slama, Jiri - Bogani, Giorgio - Kocian, Roman - Cibula, David
PY  - 2019
TI  - Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial
JF  - International Journal of Gynecological Cancer
VL  - 29
IS  - 4
SP  - 711-720
EP  - 711-720
PB  - Lippincott Williams & Wilkins
SN  - 1048891X
KW  - uterine cancer
UR  - http://dx.doi.org/10.1136/ijgc-2019-000292
L2  - http://dx.doi.org/10.1136/ijgc-2019-000292
N2  - Objectives To assess the survival of patients who have received an operation for recurrent cervical and endometrial cancer and to determine prognostic variables for improved oncologic outcome. Methods A retrospective multicenter analysis of the medical records of 518 patients with cervical (N = 288) or endometrial cancer (N = 230) who underwent surgery for disease recurrence and who had completed at least 1 year of follow-up. Results The median survival reached 57 months for patients with cervical cancer and 113 months for patients with endometrial cancer after surgical treatment of recurrence (p = 0.036). Histological sub-type had a significant impact on overall survival, with the best outcome in endometrial endometrioid cancer (121 months), followed by cervical squamous cell carcinoma, cervical adenocarcinoma, or other types of endometrial cancer (81 vs 35 vs 35 months; p<0.001). The site of recurrence did not significantly influence survival in cervical or in endometrial cancer. Cancer stage at first diagnosis, tumor grade, lymph node status at recurrence, progression-free interval after first diagnosis, and free resection margins were associated with improved overall survival on univariate analysis. On multivariate analysis, the stage at first diagnosis and resection margins were significant independent predictive parameters of an improved oncologic outcome. Conclusion Long-term survival can be achieved via secondary cytoreductive surgery in selected patients with recurrent cervical and endometrial cancer. An excellent outcome is possible even if the recurrence site is located in the lymph nodes. The possibility of achieving complete resection should be the main criterion for patient selection.
ER  -

GERMANOVA, Anna, Francesco RASPAGLIESI, Luis CHIVA, Ladislav DUŠEK, Macit ARVAS, Eric LEBLANC, Tibor LENGEYL, Violante DI DONATO, Afra ZAAL, Polat DURSUN, Ignacio ZAPARDIEL, Taner TURAN, Sergio Augusto TRIGINELLI, Sang Wun KIM, Matias JURADO, Jalid SEHOULI, Borek SEHNAL, Ladislav MASAK, Nicolae IOANID, Greta DREYER, Robert JACH, Milos MLYNCEK, Valentina CHIAPPA, Fabio MARTINELLI, Jiri SLAMA, Giorgio BOGANI, Roman KOCIAN a David CIBULA. Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial. \textit{International Journal of Gynecological Cancer}. Philadelphia: Lippincott Williams \&{} Wilkins, 2019, roč.~29, č.~4, s.~711-720. ISSN~1048-891X. Dostupné z: https://dx.doi.org/10.1136/ijgc-2019-000292.

Podrobný výpis o publikaci